Skip to main content
. 2022 Apr 21;2022:8133505. doi: 10.1155/2022/8133505

Figure 2.

Figure 2

Prognostic value of CISD2 expression in patients with glioma. (a) OS of patients with glioma in low and high CISD2 expression. (b–l) OS of patients with glioma based on low or high CISD2 expression among various subgroups, including (b) G2, (c) G3, (d) G4, (e) astrocytoma, (f) glioblastoma, (g) oligoastrocytoma, (h) oligodendroglioma, (i) IDH-wild-type status, (j) IDH mutation status, (k) 1p/19q codeletion status, and (l) 1p/19q noncodeletion status. OS: overall survival.